Compare LMND & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LMND | TGTX |
|---|---|---|
| Founded | 2015 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 5.5B |
| IPO Year | 2020 | 1995 |
| Metric | LMND | TGTX |
|---|---|---|
| Price | $75.76 | $30.81 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 4 |
| Target Price | $48.25 | ★ $54.75 |
| AVG Volume (30 Days) | ★ 2.3M | 1.4M |
| Earning Date | 11-05-2025 | 11-03-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 2.78 |
| Revenue | ★ $658,300,000.00 | $531,898,000.00 |
| Revenue This Year | $40.13 | $87.88 |
| Revenue Next Year | $59.80 | $48.75 |
| P/E Ratio | ★ N/A | $11.08 |
| Revenue Growth | 33.66 | ★ 100.88 |
| 52 Week Low | $24.31 | $25.28 |
| 52 Week High | $85.20 | $46.48 |
| Indicator | LMND | TGTX |
|---|---|---|
| Relative Strength Index (RSI) | 49.52 | 46.32 |
| Support Level | $80.22 | $29.79 |
| Resistance Level | $84.84 | $31.37 |
| Average True Range (ATR) | 5.40 | 1.00 |
| MACD | -0.71 | 0.04 |
| Stochastic Oscillator | 19.36 | 47.47 |
Lemonade Inc operates in the insurance industry. The company offers digital and artificial intelligence based platform for various insurances and for settling claims and paying premiums. The platform ensures transparency in issuing policies and settling disputes. The company is using technology, data, artificial intelligence, contemporary design, and social impact to deliver delightful and affordable insurances. Geographically, it operates in California, Texas, New York, New Jersey, Illinois, Georgia, Washington, Colorado, Pennsylvania, Oregon and others.
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries.